MNKD(MNKD)
MNKD
Next earnings: Aug 5, 2026
Signal
Mixed1↑1↓
PRICE
Prev Close
3.22
Open
3.19
Day Range3.07 – 3.21
3.07
3.21
52W Range2.23 – 6.51
2.23
6.51
20% of range
VOLUME & SIZE
Avg Volume
6.7M
FUNDAMENTALS
P/E Ratio
-44.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.34
Market-like
Performance
1D
-4.04%5D
-13.20%1M↑
+11.55%3M
-45.41%6M
-38.93%YTD↓
-45.50%1Y
-32.24%Best: 1M (+11.55%)Worst: YTD (-45.50%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +21% YoY · 76% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 1.9 · FCF $0.04/shBullish
Key MetricsTTM
Market Cap$954.66M
Revenue TTM$360.78M
Net Income TTM-$23.91M
Free Cash Flow$12.72M
Gross Margin76.0%
Net Margin-6.6%
Operating Margin3.7%
Return on Equity45.6%
Return on Assets-3.2%
Debt / Equity-7.38
Current Ratio1.87
EPS TTM$-0.08
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
2 strong2 watch2 concern
51/100Liquidity
1.87Watch
Leverage
-7.38Strong
Coverage
0.3xConcern
ROE
45.6%Strong
ROIC
1.8%Concern
Cash
$75MWatch
ANALYST COVERAGE18 analysts
HOLD
▲ +175.1%upside to target
L $6.00
Med $8.50consensus
H $10.00Stock Health
Composite Score
2 of 5 signals bullish
6/10
Technicals
●
✓RSI RangeRSI 56 — Bullish momentum
Volume
●
~Volume FlowNeutral
Fundamentals
●
✗Last EarningsMissed estimates
●
~Analyst ConsensusHold
●
✓LiquidityCurrent Ratio 1.87 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 20, 2026
In 96 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ RallyDeath Cross · 50D trails 200D by 39.2%
+10.2% vs SMA 50 · -33.1% vs SMA 200
Momentum
RSI55.9Positive momentum, not extended
MACD+0.12Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$6.51+110.7%
EMA 200
$4.14+33.9%
EMA 50
$3.26+5.6%
Current
$3.09
52W Low
$2.23-27.8%
52-Week RangeNear 52-week low
$2.2320th %ile$6.51
Squeeze SetupVolume-based
No Clear SetupVolume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
20-Day Money Flow
Acc days:1
Dist days:3
Edge:+2 dist
Volume Context
Avg Vol (50D)6.0M
Recent Vol (5D)
5.2M-13%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 6 analysts
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $342.4M $323.4M–$369.6M | — | $0.17 | — | ±7% | High6 |
FY2026(current) | $459.9M $449.8M–$471.4M | ▲ +34.3% | -$0.02 | — | ±50% | High6 |
FY2027 | $518.3M $491.8M–$545.0M | ▲ +12.7% | $0.14 | — | ±50% | High6 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryMNKD
Last 8Q
-24.3%avg beat
Beat 3 of 8 quartersMissed 4↓ Estimates falling+250%
Q3'24
-33%
Q4'24
—
Q1'25
+33%
Q2'25
-95%
Q3'25
+200%
Q4'25
-400%
Q1'26
-150%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →1 Buy/5 SellsNet Selling
NET SELLERS$0 bought · $66K sold · 30d window
Binder Steven B.Dir
$56K
May 12
SELL
Thomson DavidEVP Genl Couns…
$10K
May 12
SELL
Castagna MichaelCEO
$259K
Mar 10
BUY
Tross Stuart AChief People &…
$298K
Jan 8
SELL
Castagna MichaelCEO
$395K
Dec 17
SELL
Castagna MichaelCEO
$128K
Dec 16
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
28.6M▼2
STATE STREET CORP
18.7M▲3
UBS Group AG
8.3M▲4
GEODE CAPITAL MANAGEMENT, LLC
7.5M▲5
MILLENNIUM MANAGEMENT LLC
6.4M▲6
Frazier Life Sciences Management, L.P.
5.9M▲7
MORGAN STANLEY
5.8M▲8
DIMENSIONAL FUND ADVISORS LP
5.0M▲News & Activity
MNKD News
About
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Michael Castagna
Country
United States
Website
David ThomsonExecutive Vice President, General Counsel & Secretary
Dominic MarascoPresident of Endocrine Business Unit
Sanjay SinghExecutive Vice President of Technical Operations
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
MNKD◀ | $3.09 | -4.04% | $955M | — | +2222.8% | 168.0% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.12% | — | 50.3 | +342167.4% | -3477.9% | 1500 |